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ABSTRACT
EFFECTS OF ERBB2 VACCINATION ON THE MURINE HEART. Sumayya Ahmad,
Renelle Gee, Kerry Russell, and Mark J. Mamula. Section of Rheumatology, Department of
Internal Medicine, Yale University School of Medicine, New Haven, CT 06510.

ErbB2, a member of the epidermal growth factor receptor family, is found in many tissues of the
body. It is known to potentiate growth via vascularization and anti-apoptotic signals, amongst
other things. Its presence on breast cancer cells results in a particularly poor prognosis. A novel
monoclonal antibody targeting this receptor, Herceptin, allows precise targeting of these cells and
results in longer life spans for these patients. However, early trials of the biologic agent
demonstrated that up to one third of patients taking Herceptin get depressed cardiac function
when taking the drug in conjunction with Doxorubicin, a common first-line chemotherapeutic
agent. Since its creation, the mechanism of action of Herceptin on the heart, and in particular its
affinity for the cardiac ErbB2 receptor, has been profoundly explored. However, potential
autoimmune mechanisms of cardiac dysfunction with anti-ErbB2 agents have not been
investigated previously.

We examined the effects of a peptide vaccine (p601) targeting a 16 amino-acid sequence on the
extracellular region of ErbB2 on immune responses and cardiac function in mice. Unpublished
data from our lab showed that genetically engineered mice with ErbB2+ tumors demonstrated
tumor decline when immunized with this vaccine. To accomplish this, we performed
echocardiography on immunized mice to assess cardiac function and serologic and
immunohistochemistry studies to examine the immune reactivity to ErbB2 and to heart muscle.
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We found that immunization of Balb/c mice with p601 did not result in echocardiographic
abnormalities. However, p601-immunized FVB mice in which ErbB2 was up-regulated
demonstrated arrhythmias not found in any other mice. Furthermore, ErbB2-immunized mice sera
as well as Herceptin bound to the extracellular domain of ErbB2 as well as heart lysate not found
in PBS controls. After analyzing the western blot via spectrometry, we discovered that the bound
region contained alpha cardiac myosin heavy chain. A BLAST search revealed a homologous 8
amino acid peptide region between myosin and ErbB2, suggesting that anti-ErbB2 agents may be
binding a component of myosin. Immunofluorescence staining revealed increased non-specific
anti-IgG binding to immunized mice hearts compared to PBS controls. Furthermore, H&E stain
revealed increased leukocyte adhesion to the surface of arterioles in a Balb/c immunized control.
FVB immunized mice that demonstrated arrhythmias also had sarcomere destruction in addition
to leukocyte adhesion to the surface of arterioles.

Because mice immunized with two synthetic peptides spanning the homologous region of ErbB2
and myosin did not develop ErbB2 reactivity or echocardiographic abnormalities, we looked for
evidence of complement deposition in mouse hearts immunized with the p601 and the anti-ErbB2
and myosin peptides. Examination of tissues by immunohistochemistry revealed increased C3
staining in small pockets of ventricular tissue in p601-immunized controls as compared to both
PBS and anti-ErbB2 and myosin peptides. Since such staining is not typically found in
autoimmune heart disease, it may indicate another process of immunological destruction, such as
immune complex deposition. Our studies suggest an autoimmune mechanism for the action of
anti-ErbB2 agents on the heart, in contrast to previous studies that have focused on the effects of
receptor binding and signal transduction on the cardiac ErbB2 receptor.
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INTRODUCTION:
Overview
There will be an estimated 207,090 cases of breast cancer in 2010; 40,230 women are expected to die of
the disease (1). Its prognosis depends on several factors, including staging, type (such as the presence of
certain components of the cancer cells), and the age and general health of the woman. Malignancy
containing a growth factor receptor, ErbB2 (also called Her2/Neu), has a particularly poor prognosis.
Patients with ErbB2+ breast cancer have reduced survival than other types. The reasons for this are
varied; these tumors tend to grow faster and are generally more likely to recur than tumors that do not
overproduce ErbB2.

A novel monoclonal antibody targeting this receptor has been manufactured, providing such patients with
hope in an otherwise dismal prognosis. This agent, called Herceptin, is not without untoward side effects,
however. Early trials of the drug demonstrated that up to one third of patients taking Herceptin get
depressed cardiac function when taking the drug in conjunction with Doxorubicin, a common first-line
chemotherapeutic agent. Dysfunction included asymptomatic depression of left ventricular ejection fraction
as well as congestive heart failure. Since these trials, the mechanism of action of Herceptin on the heart has
been under heavy investigation. Although Doxorubicin is known to independently alter cardiac function,
patients receiving both agents had a higher rate of dysfunction than if taking either drug alone.

Our laboratory recently found that a peptide vaccine targeting a 16 amino-acid sequence on the
extracellular region of ErbB2 distinct from the Herceptin binding site can induce tumor regression in
mice engineered to produce ErbB2+ tumors. In various unpublished studies from our lab, sera from
vaccinated mice were also found to have antibody reactivity to not only the peptide but also to a
wider range of proteins. We thus examined the hypothesis that vaccine-induced antibodies may
prevent heart failure while inducing tumor decline. If this was the case, our theoretical vaccine could
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be a potential candidate for patients. If it did not, we would be able to more closely examine the
effects of Herceptin and potential effects via autoimmunity on the heart, as induced by vaccination.

The ErbB Receptor
Epidermal growth factor (EGF) was first described in 1965, when Cohen and colleagues
described the growth of epidermal and corneal cells in response to a certain substance(2). EGF
was later described to be a peptide of 53 amino acids with 6 cysteine residues. The cysteine
residues form three disulfide linkages that are essential for biological activity of the growth
factor. To date, eleven EGF-like peptides have been described, which encompass the EGF family
of growth factors. The family includes transforming growth factor (TGF)-α, amphiregulin (AR),
heparin-binding EGF (HB-EGF), epiregulin (EPR), betacellulin (BTC), and the neuregulins 1–4
(NRG1-4)(3, 4). Since the isolation of these growth factors, EGF was found to be in various
tissues in the body including amniotic fluid, milk, saliva, gastric contents, bile, and urine,
amongst other tissues(5). The highest levels of EGF are found in the brain, thyroid, lung, liver,
skin, placenta, and fetal membranes. GF has been implicated in palate and skin differentiation,
growth of hair follicles, eye opening and tooth eruption, lung maturation, gut and liver growth,
and differentiation of neurons(6-8).

After the discovery of the substance, a search went underway to discover the receptor for the
factor. In the 1970’s, a 170-kda protein was discovered to cross-link EGF. At the time, the protein
was also discovered to have intrinsic tyrosine kinase activity. To date, four members of epidermal
growth factor receptors have been described, which are sequentially named as ErbB1/Her1,
ErbB2/Her2/Neu, ErbB3/HER3, and ErbB4/HER4(4, 7, 9, 10). The ErbB2 receptor in particular
is a 185 kda transmembrane glycoprotein(11). With the exclusion of hematopoietic tissues, all
cell types possess EGFRs. The ErbB2 protein is also found in epithelial cells of many normal
tissues in healthy adults.
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Table 1: ErbB Receptors in Humans
Name

Tissue Distribution
(not limited to those
listed)

ErbB1/Her1

ErbB2/Her2/Neu

Epithelial tissue,
myocardium

ErbB3/Her3

ErbB4/Her4

Neural tissue,
epicardium and
atrial/ventricular
myocardium

Ligands

Epidermal growth factor (EGF),
transforming growth factor-a
(TGFa),
epiregulin (EP), amphiregulin
(AR), betacellulin (BTC),
heparin-binding
EGF-like growth factor (HBEGF)
Unknown

Neuregulin (NRG1)/heregulin(HRG) isoforms,
NRG-2a and b
NRG-1/HRG isoforms, NRG2a and b, NRG-3, NRG-4,
tomoregulin
HB-EGF, BTC, EP

Interesting
Properties

Forms dimers
with all other
ErbB receptors,
known
oncoprotein
Lacks intrinsic
kinase activity

The three components of the ErbB receptor include the extracellular, transmembrane, and
intracellular domains. The 600 amino acid extracellular component of the receptor has four
distinct subdomains: domains I, II, III, and IV. Domains I and III share approximately 37% amino
acid sequence identity, whereas domains II and IV share 17% sequence identity and are cysteine
rich. EGF activates its receptor by inducing dimerization of the 621 amino acid EGF receptor’s
extracellular region. The receptor-binding domain is part of a large transmembrane region
containing other motifs such as heparin-binding sites and glycosylated linkers. The structure of
the extracellular domain is auto-inhibited unless bound by a ligand. Once a ligand initially binds
to domain I and the initial connection is established, hydrogen bonds rupture between cysteinepositive domains II and IV, allowing a conformational change and high-affinity interaction with
domain III. Such studies have confirmed the hypothesis that ligand binding induces a
conformational change in the extracellular domain of EGFR, exposing a dimerization site that is
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normally in an inactivated conformation(12). All four ErbB receptors share the described
extracellular domains(13, 14).

The transmembrane domain of the EGFR has 23 amino acids. This portion of the receptor allows
dimers to form when a ligand is attached to the extracellular portion of the domain. The
transmembrane domain also aligns the intracellular kinase domain upon dimerization(15-17).

The cytosolic portion of the receptor has several components that include a tyrosine kinase (260
aa), juxtamembrane region (40 a.a.), and a carboxy-terminal region (232 a.a.). The EGFRs are
unique from other tyrosine kinase receptors in that the kinase domain is constitutively active
without needing to be phosphorylated. Regulation is likely exerted by control of the delivery of
COOH-terminal substrate tyrosines to the active site(18, 19). In addition to autophosphorylation
of tyrosine, threonine and serine residues are also phosphorylated by downstream kinases part of
the EGFR-activation cascade.

The ligands for the EGFR family bind variably to the four receptors. For example, it is known
that both NRG1 and NRG2 bind directly to ErbB3 and to ErbB4 and employ ErbB1 and ErbB2 as
co receptors. ErbB2 has no known direct ligand, but is known to forms dimers with all other
families of ErbB via lateral signaling(20). ErbB1 and ERbB4 binds six known molecules: EGF,
transforming growth factor α, heparin-binding EGF-like growth factor, amphiregulin, epiregulin,
and betacellulin(21).

The conformational change induced by ligand binding does not only induce dimerization within
the individual receptor, but can also result in(20) the formation of homodimers with other EGFRs.
It is also well established that activation of certain types of ErbB receptors necessitates horizontal
activation with other types (22, 23). This process is thought to be mediated via rotation of
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domains I and II, which change from a tethered configuration to an extended configuration(24).
ErbB3 is devoid of intrinsic kinase activity, whereas ErbB2 seems to have no direct ligand;
therefore, in isolation neither ErbB2 nor ErbB3 can support linear signaling.

The downstream signaling pathways of EGF receptors are diverse. The mitogen-activated protein
kinase (MAPK) pathway is an invariable target of all ErbB ligands. MAPKs are important signaltransducing enzymes that are involved in many aspects of cellular regulation, ranging from gene
expression, cell proliferation, cell survival and death, and cell motility. The PI(25)K-activated
AKT pathway and p70S6K/p85S6K pathway are the most highly activated pathways of ErbB
dimers. Phosphatidylinositol 3-kinase (PI3K) produces phosphatidylinositol(26-28) triphosphate
and is activated by AKT, a protein kinase that triggers a cascade of responses modulating cell
growth, proliferation, and survival(29, 30). Other signaling molecules that are activated by
EGFRs include Ras, phospholipase c, JAK/signal transducers, and NF-κB(31). Ligand-mediated
receptor endocytosis turns off signaling by the ErbB network.

Studies have revealed that the EGF receptor is also part of signaling networks triggered by stimuli
that do not directly interact with this receptor. Such stimuli, including membrane depolarization
agents and environmental stressors, bind to other membrane receptors and induce horizontal
transactivation of the ErbB pathways. The indirectly binding pathways include G-protein linked
receptors, membrane depolarization via intracellular calcium signaling, and stress responses via
exogenous physical and chemical stimuli (including arsenite, oxidants, gamma irradiation,
amongst others)(32). The G-protein coupled receptor (GPCR) in particular has been known to
activate the MAP kinase pathway via ErbB2 tyrosine phosphorylation. Studies have also revealed
that the transactivation of EGFR is an obligatory event for the stimulation of protein synthesis by
GPCRs. The ligands that can induce these changes include endothelin-1, lysophosphatidic acid,
and thrombin(33-35).
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The importance of the EGFR family of receptors in development has been tested in knockout
mice studies, which demonstrated that such mice die either during or shortly after gestation. The
mice that do survive have central nervous system defects, as well as abnormalities in their skin,
kidney, brain, liver, eyes, teeth, and GI tract(36, 37). Thus, EGF has been described as an
embryotrophic factor since it enhances mitogenesis, development, and implantation in
mammalian species. In addition to development, it is thought to result in the morphogenesis of
many organs(38, 39).

EGF has also been implicated in cytoprotection, accelerated wound healing, cardiac dysfunction,
cell survival regulation, as well as normal epithelial regeneration. The diversity of these actions
has been linked to the discovery of EGFR on various cell types, receptor expression and density
levels, as well as ligand concentrations(39, 40).

The ErbB Receptors in Cancer
Tumors are unique in that they respond in an unlimited way to growth signals, are insensitive to
anti-growth signals, have unrestricted replication potential, and also manage to escape from the
immune system’s regulatory mechanisms. They are able to induce angiogenesis and colonize new
locations for growth. Abnormal EGFR signaling alone can produce many of these features, since
the downstream signals code for many important cellular processes(31). EGFR is expressed in
lung, pancreas, breast, head and neck, ovarian, renal, colorectal, and prostate cancer. ErbB2 is
highly expressed in breast, ovary, and lung carcinomas, where its presence is generally associated
with a more aggressive phenotype and worse patient prognosis, including reduced survival(4144).

Several mechanisms have been implicated with the increased malignant potential of EGFR
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positive cancers. They include amplified downstream signaling, increased receptor expression,
defective down regulation, expression of constitutively active mutants, and increased crosstalk
with other receptors. Genetic amplification are responsible for most of these defects but mutations
have also been linked in a variety of cases(31).

The genetic mutations in the EGFR gene involve various components of the receptor. Tyrosine
kinase mutations are almost exclusively linked with lung cancer and display evidence of
anchorage-independent growth and tumor formation. Such alterations are present in the first four
exons of the gene encoding the tyrosine kinase domain(45). Tyrosine kinase inhibitors such as
Gefitinib and Erlotinib are used as chemotherapy. Glioblastomas, on the other hand are
associated with deletion mutations, resulting in a deletion of 270 amino acids on the extracellular
domain of the receptor. These brain tumors are related to ErbB3, which becomes constitutively
active and ligand-independent(46).

Multiple downstream pathways have been linked to the increased malignant potential of EGFRs.
Since the PI3K pathway modulates cell growth, proliferation, and survival, it has been implicated
in tumor growth and progression. Both the MAP kinase AKT pathways signal transcription via
proto-oncogenes such as fos, jun, and c-myc, which up-regulates the expression of p53. Finally,
NF-κB and STAT signaling are known to increase the amount of pro-survival proteins like B-cell
lymphoma X(23, 47).

ErbB2 has been studied extensively because of its over-expression in multiple types of cancer,
including lung, carcinoma, and breast cancers. It plays a central role in tumor progression due to
the prolongation of the signal cascade of the other ErbB receptors and its increased resistance to
host defenses through evasion of the immune system(48, 49). Recently, there has also been
evidence that ErbB2 expression rescues detached cells from energy depletion by maintaining their
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glucose uptake(27).

ErbB2 positive cancers are often the result of gene amplification, resulting in up-regulation of the
receptor. Up-regulation increases EGFR-ErbB2 heterodimerization; such heterodimers are more
insufficiently degraded than EGFR homodimers. This results in more potent transformation
compared to the other EGF receptors(50). In the case of receptor over-expression of ErbB2,
horizontally linked homodimerization with all other ErbB2 receptors has been established. This is
due to the fact that unlike the other EGFRs, the ErbB2 domains I and III are strongly interactive,
allowing ErbB2 to continuously assume the open conformation without a ligand(51). The active
conformation of ErbB2 is maintained through interactions with chaperone heat shock protein 90
(Hsp90). Drugs such as Geldanamycin have the potential to antagonize Hsp90, preventing
downstream signaling.

ErbB2 over-expression results in up-regulation of protease activities and increased invasiveness
of breast cancer cells and VEGF expression, which when coupled together can lead to a stronger
angiogenic response. Increased secretion of proteases can result in increased membrane
degradation and invasiveness of the tumor. These effects, combined with the constitutive
activation of the ErbB2 receptor and its ensuing downstream signaling, produce continual
expression of pro-mitotic and pro-metastatic cells(26).

Finally, it must be said that although mutations and over-expression of ErbB receptors are often
associated with cancer, other diseases are also linked to alterations in the receptor. They include
polycystic kidney disease, cirrhosis, inflammatory bowel disease, and chronic asthma.

Breast cancer is the most common malignancy amongst women in the United States, with a new
incidence of 192,370 and 40,170 deaths(1). The ErbB2 gene is amplified in approximately 20-
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30% of human breast cancers. Patients with up-regulation are generally considered to have a
poorer prognosis than those without. One study found ErbB2 over-expression in breast cancer
was associated with a shorter 5-year overall survival rate compared with ErbB2-negative cases.
Over-expression was also present with statistical significance in node-positive patients compared
to node-negative patients(52). These results indicate the importance of screening patients with
breast cancer for ErbB2 protein and gene expression, which is routinely performed in patients
with node-negative breast cancer. Methods for screening include fluorescence in-situ
hybridization and southern blotting.

Because of the strong association of ErbB2 and malignancy, scientists attempted to discover
selective ErbB2 targeted therapies. The hope was to prevent the growth of the aforementioned
survival pathways, resulting in tumor stasis and growth inhibition.

Herceptin Therapy: Antibodies Targeting ErbB2
Herceptin (Trastuzumab) is a monoclonal antibody that targets ErbB2 receptors. It has been used
effectively in combating ErbB2 positive breast cancer. It has also been used for regression of
tumor growth in uterine cancer. This drug, when used as first line treatment in combination with
standard chemotherapy, increases the time to disease progression, the objective response rate, and
overall survival rates compared with standard chemotherapy alone(28). The mechanism of action
of this drug against cancer cells is multifold. It has been shown to induce antibody-dependent
cellular toxicity (via natural killer cells), block the proteolytic cleavage of ErbB2 extracellular
domain, inhibit intracellular growth factors, and prevent angiogenesis around tumor sites(53, 54).

Herceptin contains an IgG structure with an Fc binding domain that induces natural killer cells to
attract other immune effector cells to destroy the target. Studies in which the Fc receptor was
deleted displayed substantially less growth inhibition. Another study identified a specific Fc
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receptor type that was associated with an improved objective response rate and progression-free
survival(55, 56). Human ErbB2 and Herceptin fragment antigen binding site is demonstrated
below(51):

From Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone
and in complex with the Herceptin Fab. Nature 2003;421:756-60.
Decreased expression of VEGF has also been demonstrated in patients taking Herceptin. One
study demonstrated a 50% downregulation of VEGF, TGF-α, plasminogen activator inhibitor 1,
and angiopoietin 1. Studies of the induction of the downstream pathways of EGFR have been
varied. Some studies demonstrated no limitations on cell growth and survival, whereas others
have shown inhibition of phosphorylation, inhibiting the MAPK and P13K pathways(57, 58).

Cardiac Dysfunction in Herceptin-Treated Patients
Although pre-clinical studies did not reveal cardiac toxicity, the first phase III trial revealed
cardiac dysfunction amongst its enrollees. The adverse effect noted was cardiac dysfunction in
women who received an anthracycline plus Herceptin. In one randomly controlled clinical trial
studying the safety of Herceptin, there was evidence that cardiac dysfunction occurred in 27% of
women given anthracycline plus cyclophosphamide plus trastuzumab compared with 8% given
anthracycline plus cyclophosphamide, 13% given paclitaxel plus trastuzumab, and 1% given
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paclitaxel alone. In this study, increasing age was the only base-line characteristic that was a
significant risk factor for cardiac dysfunction in patients who were receiving the combination of
an anthracycline, cyclophosphamide, and Herceptin(28). The prevalence of stage III or IV heart
failure, which severely limits physical activity, was most marked in patients who took all three
agents. The overall conclusion of the study was that cardiotoxicity was potentially severe and
sometimes life threatening but responsive to medical management.

Another, larger clinical trial called the Herceptin Adjuvant (HERA) Trial, followed 1,693 patients
taking Herceptin in conjunction with other chemotherapeutic agents and 1,693 taking
chemotherapy without Herceptin for one year. 4.3% of patients discontinued Herceptin due to
cardiac related events; patients taking Herceptin had a higher incidence of developing the
following cardiac endpoints: severe congestive heart failure (CHF), 0.60% v 0.00%; symptomatic
CHF, 2.15% v 0.12%; confirmed significant depression of left ventricular ejection fraction
(LVEF), 3.04% v 0.53%)(59). Although CHF and decline in LVEF accounted for the majority of
cardiac disease in this trial, other cardiac endpoints included manifestation of coronary artery
disease (n=1), tachyarrhythmias (n=2), pericardial effusion (n=1), new ECG abnormalities (n =2),
and nonspecific cardiotoxicity (n =4). Patients with cardiac abnormalities were treated with a
higher dosage of the anthracyclines Doxorubicin or Epirubicin.

It must be noted that anthracyclines can independently result in cardiac failure. Doxorubicin in
particular is composed of a naphthacenequinone nucleus linked through a glycosidic bond to an
amino sugar, daunosamine(60). The structure is below(60):
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Classification of anthracycline-induced cardiac failure falls into three categories: acute, earlyonset chronic progressive cardiomyopathy, and late-onset chronic progressive cardiomyopathy.
Acute onset occurs within the first week of anthracycline treatment, results in transient depression
of myocardial contractility, and is often reversible when the anthracycline is discontinued. Earlyonset chronic progressive myopathy occurs less than a year after completion of treatment, is
characterized by dilated cardiomyopathy in adults, and can be progressive. Finally, late-onset
cardiotoxicity occurs greater than a year after completion of treatment and also results in dilated
cardiomyopathy that can be progressive(61).

Several mechanisms have been proposed for the cardiotoxicity of anthracyclines. The quinone
moiety can undergo reductive and oxidative transformation, resulting in highly reactive chemical
species. This process may be responsible for acute cardiac dysfunction. Secondary alcohol
metabolites are also produced via reduction of the carbonyl group side chain and may be
responsible for chronic dysfunction(62). Studies have also suggested that anthracycline-induced
apoptosis can be activated via both reactive oxidative species as well as secondary alcohol
metabolites. Effects of these changes can result in disruption of the cardiac sarcomeric structure,
possibly via accelerated degradation of sarcomeric proteins and disruption of new protein
synthesis(62).
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Interestingly, later studies demonstrated the reversibility of cardiac dysfunction upon termination
of Herceptin chemotherapy(62). Other studies have since validated this finding(63, 64).
However, the study behind the initial mechanisms of Herceptin-induced heart failure remains an
important and vibrant research topic.

Herceptin Cardiotoxicity: In-Vitro Studies of Mechanisms of Action
There are four mechanisms of Herceptin-mediated cardiotoxicity that have been proposed:
immune-mediated destruction of cardiomyocytes, drug-to-drug interaction with anthracyclines,
impaired ErbB2 signaling necessary for the maintenance of contractility, and interference with
cardiomyocyte survival signals(65).

Much research has shed light on mechanisms related to impaired ErbB2 signaling and drug-drug
interaction with anthracyclines. These two processes may be related. For example, it is known
that reduction of ErbB2 signaling augments cardiomyocyte apoptosis. This appears to be
modulated via pathways such as Akt. Cell death may be achieved via a mitochondrial pathway
that produces reactive oxidative species. The same study found a decrease in ErbB2 receptors in
ischemic hearts, indicating that there is a link between ErbB2 and cardiomyocyte growth and
survival(54). Interestingly, these anti-apoptotic features of ErbB2 signaling may come in useful
when exposed to environmental trauma that induce cardiomyocyte death via oxidative stress,
such as exposure to anthracyclines(66). In fact, some studies have demonstrated ErbB2 upregulation in patients with anthracycline-related heart failure compared to patients without
anthracycline-related heart failure(67). Coupled with the antagonizing effects of Herceptin
therapy, this model may partially explain the greatly increased rate of cardiotoxicity in patients
taking Doxorubicin and Herceptin concurrently.
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The role of Herceptin as an antagonist to survival signals may also be a contributing factor to its
cardiotoxicity. The anti-apoptotic attributes of ErbB2 may be modulated by local mediators such
as neuregulin, which is produced by endocardial and microvascular endothelial cells and acts on
ErbB2 and ErbB4 receptors(68). It is thought that the amount of neuregulin produced varies from
one individual to the next, and depends upon genetic factors as well as environmental stressors.
One study demonstrated that EGF and Neuregulin-1β were cardioprotective against the acute
stress of low-flow ischemia and epinephrine. The study found increased phosphorylation via the
ERK and Akt pathways, highlighting the cardioprotective role of the ErbB2 signaling cascade in
myocytes(69).

Furthermore, ErbB2 is also thought to play a role in cardiomyocyte growth and survival in utero.
For example, the function of ErbB2 and other ErbB receptors on the heart is variable throughout
life; adult myocardium expresses ErbB2 and ErbB4 but not ErbB3, whereas neonatal
myocardium expresses all three. It is also known that transgenic mice with cardiac-restricted
deletion of ErbB2 survive embryogenesis but develop a cardiomyopathy in adulthood that is
similar to those observed in patients treated with Herceptin(70). Although irreversible
cardiomyopathy develops in genetically engineered mice deficient in ErbB2, there is little
evidence of anti-ErbB2 induced cell death in normal adult myocardium exposed to anti-ErbB2
agents, perhaps explaining the reversibility of the heart damage induced by Herceptin(65).

Although much light has been shed on non-immune related pathways of cardiac dysfunction, the
theory of an immune response against the heart has also been proposed. Studies have
demonstrated that Herceptin induces antibody-dependent cellular cytotoxicity (ADCC) mostly via
monocytes and natural killer cells on cells that over-express ErbB2, but not on cells that do not
over-express ErbB2. Complement mediated tumor lysis proportional to the amount of ErbB2 on
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cell surfaces has also been demonstrated(71). Although both of these have been in vitro studies,
there is a link between Herceptin and an immune response within the body.

Herceptin Cardiotoxicity: In Vivo Studies
Finally, the type of heart damage induced by anti-cancer drugs varies. Anthracyclines cause Type
1 cardiotoxicity, which is defined by a dose-dependent response and presents as microscopic
structural myocardial abnormalities such as vacuolization, myofibrillar disarray, and myocyte
necrosis. Herceptin therapy, in contrast, causes Type 2 cardiotoxicity, which occurs sporadically
in a dose-independent fashion and appears to be reversible. Type 2 cardiotoxicity manifests with
a wide range of severity and is not related to identifiable structural cardiomyocyte changes(65).
5% of patients receiving Herceptin monotherapy were found to have tachycardia. There also have
been some case reports of patients on Herceptin therapy who have developed atrial fibrillation,
bradycardia with t wave inversions, and left bundle-branch block(72, 73).

Heart biopsies of patients with Herceptin-related cardiotoxicity have demonstrated no structural
damage, such as myofibrillar disarray(62). However, Sawyer and colleagues found that there was
increased myofibrillar disarray in myocardium of rats treated with an anti-ErbB2 agent and an
anthracycline when compared to rats treated with an anthracycline alone, indicating that there is a
modulatory effect of cardiac damage due to ErbB2 receptors(66). This is consistent with the
findings in the initial phase III trial demonstrating an increased rate of heart damage in patients
with concurrent Herceptin and anthracycline therapy.

Vaccine Therapy vs. Monoclonal Antibody Therapy
The purpose of the current study was to determine if a potentially therapeutic ErbB2 peptidebased vaccine designed by our laboratory had adverse cardiac effects in mice, similar to those
reported for Herceptin. It is important to distinguish between vaccination and Herceptin therapy.

16
Monoclonal antibodies like Herceptin are produced in vitro from hybridomas formed by the
fusion of activated B lymphocytes to plasmocytoma cells, thus creating a monoclonal antibody
directed against a single epitope. In contrast, a vaccine stimulates an antibody response initially to
the protein immunogen, which then can expand to other epitopes on the targeted molecule, in this
case ErbB2, and even to molecules that may form complexes with the target protein (70). The
mice in our model were immunized with a peptide that induced a polyclonal response and likely
targeted multiple epitopes on the ErbB2 protein.

Epitope spreading, or the expansion of immune responses to multiple antigenic determinants, is a
phenomenon originally described in the context of autoimmunity. Both B and T cell epitopes can
expand with continued exposure to an antigen. The most effective way for the body to clear a
pathogen is to attack as many different sites on the pathogen as possible; it would in fact, be
difficult to find an immune response to a pathogen or protein directed toward only a single
epitope.

The mechanism by which this can happen is multi-factorial. Macrophages and dendritic cells
(antigen presenting cells, or APCs) can couple with immune complexes (antigen and antibody) or
just antibodies via Fc receptors on their surface. These cells can then activate cytotoxicity and
killing, via mechanisms ranging from cytokine release, to natural killer activation, to direct
phagocytosis (74, 75). APCs present foreign or molecular antigens to T cells, which in turn
provide conventional help to B cells. (See Figure 1). After processing and post-translational
modification, B cells can then proliferate with receptors binding the original antigen presented—
and activate a plethora of T cells. Furthermore, B cells can also present novel determinants of the
original protein for a second round of T cell induction. B cells can also uptake antigen
themselves, inducing a T cell response to diverse peptides(76). (See Figure 2). In this way,
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epitope spreading occurs, with the end result of an armament of T cells driving B cell production
of antibodies against multiple components of an antigen or particle.

Immune responses to an antigen can alter protein processing by APCs to expose epitopes of self
proteins not normally produced during antigen processing and presentation (so called “cryptic”
epitopes). In order for the body to produce antibodies directed against a self-protein, several
components of the antigen-presenting and processing course must go awry. APCs must costimulate T cells (which in turn stimulate B cells) and B cells themselves must break self
tolerance in T cells when presenting antigenic determinants (perhaps via a co-stimulatory
molecule). Finally, there must be a large amount of the cryptic antigen available for up-take by B
cells.

Figure 1:Antigen-Presenting Cells (APC’s) present antigens, immune complexes, or potentially
cryptic self determinants to T cells
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Figure 2: Epitope Spreading via B cells through T cell priming and activation

The process detailed above can be applied to patients taking Herceptin. The immune response to a
monoclonal antibody is more complex than was initially assumed. When an antibody targets a
cellular receptor and induces damage (as in ADCC), self-proteins are released. These self
proteins, some of which may be modified by Herceptin binding, are then taken up by APCs and
induce further immune responses, via T and other immune cells (74). Therefore, the self-proteins
released in this process can become immunogenic, resulting in a polyclonal response to multiple
protein determinants on the same self-particle(77). Herceptin could thus induce an immune
response to epitopes on ErbB2 not targeted by the mAb. Unpublished data from our laboratory
indicates that there exist such epitopes in the sera of patients being treated with Herceptin.

Hence, peptide-based immunization of mice may also present a good model to study the epitope
expansion seen in patients on Herceptin therapy, in addition to being a potential new treatment.
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Efficacy of Cancer Vaccines
Vaccines are a highly studied potential source of cancer treatment. The aim is to enable the
immune system to recognize tumor cells and use its own mechanisms to destroy tumors. To date,
no vaccines have been mass-produced that protect against an established cancer. However, many
studies are underway to exploit the potential of vaccines. Vaccination strategies include the use of
whole proteins and peptide vaccines based on sequences recognized by cytotoxic T lymphocytes
and recombinant viruses encoding these peptide epitopes(74). Scientists have recently been
developing vaccines based on tumor cells taken from patients and made immunogenic by the
addition of adjuvants, or by combining autologous dendritic cells with tumor-cell extracts or
tumor antigens(74). The problem with dendritic cell based vaccines is the inability of dendritic
cells to migrate to lymph nodes from the immunization site. Peptide based vaccines are unique in
that they are able to elicit an immunological response against specific sites on an antigen and can
stimulate immunity to cover multiple components on the surface of an antigen. Furthermore they
can be adapted to be used with adjuvants to elicit a predetermined immune response(73). They
are also easier to store (available in powder form), are stable indefinitely, and are able to be
delivered intra-nasally and transdermally(73).

Immunological Resistance to Cancer Vaccines
Despite the promise that vaccines hold for cancer patients, evidence shows that many tumors are
resistant to vaccines. Many tumors do not express proteins that can overcome tolerance to self or
the co-stimulatory molecules necessary to begin such an immune response. Tumors also have
other ways of avoiding or suppressing the immune response, such as not expressing MHC class I
molecules or producing cytokines. Lacking these surface molecules means that T cells can no
longer recognize them and therefore, they evade the immune response. Other tumors are able to
release immunosuppressive cytokines(78). Many studies underway are examining other
mechanisms by which tumors can out-smart the immune system.
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Vaccines Targeting ErbB2
Self-reactive antibodies to ErbB2 may arise spontaneously in patients with ErbB2 positive
cancers. Several investigations have defined the incidence of ErbB2 antibodies in patients with a
variety of carcinomas. One study found ErbB2 antibodies at titers of >1:10 in 11% of breast
cancer patients versus 0% of controls (p < 0.01). However, some of these studies also
demonstrated that high immunological titers did not correspond to a decrease in tumor size(79,
80). Therefore, scientists have attempted to boost the immune response via immunization.

Although several studies have suggested that it is best to vaccinate cancer patients with minimal
residual disease after treatment, when the tumor burden is lowest, active immunization against a
particular protein such as ErbB2 in the early stages of the cancer may prevent antigen-over
expressing malignancies. Peptide-based vaccines are ideal for this scenario, in that they are
innately specific for a given protein antigen. Disis and colleagues enrolled 63 patients with latestage breast cancer in a study immunizing them with peptide antigens to either the intracellular or
extracellular domain of ErbB2. All the vaccines were well tolerated, with the worst side effects
being myalgia and rash. Greater than 50% of the patients in the study demonstrated active T cell
immunity against ErbB2 positive cell lines, as measured by T cell proliferation assays(79).

Other studies have also experimented with producing vaccines targeting ErbB2. Alvarez-Nueda
and colleagues discovered that a llama single-domain antibody was able to elicit a strong
immunological response in mice against ErbB2.The researchers discovered that the antibody was
able to mimic the three-dimensional features of ErbB2 and to induce an anti-ErbB2 humoral
immune response in mice(81).

Another clinical study injected patients with an ErbB2 intracellular domain-containing dendritic
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cell vaccine. The patients had no cardiac defects as measured by echocardiography and 100%
were alive and disease-free at 4.5-year follow-up(82). Although there were only seven patients
enrolled in this report, it provides support for a heart-safe anti-ErbB2 vaccine in the future.

Statement of Purpose
The purpose of the current study was to determine the cardiac side effects of a novel peptidebased ErbB2 vaccine designed by our laboratory and tested in mice. Our vaccine, called p601, is
a 20 amino acid peptide structure that matches a sequence on the extra-cellular domain of ErbB2.
A BLAST search revealed that this peptide sequence is highly specific for ErbB2 receptors on
human and rat cells. Previous studies from our lab (unpublished) demonstrated that there was a
decrease in tumor size and less nodal metastases in mice with ErbB2+ cancer that had been
immunized with p601, compared to controls immunized with saline in adjuvant. The goal of this
study was to determine whether the p601 vaccine would also have the adverse effect of cardiac
toxicity similar to that observed with Herceptin therapy.
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MATERIALS AND METHODS:
I completed all the experiments outlined below unless otherwise indicated.

Mice
Balb/c were obtained from Jackson Laboratories and used at age 6 weeks. FVB mice carrying
wild-type rat neu driven by the mouse mammary tumor virus (MMTV) promoter (FBV-rat
ErbB2+ mice) were also used. Mice were housed and cared for according to standards set by the
Yale Animal Care and Use Committee.

Antigens
The p601 vaccine was composed of a 20 amino-acid peptide sequence of the extra-cellular
domain of both mouse and human ErbB2 (amino acid sequence:
PSGVKPDLSYMPIWKFPDEEG). Two peptides corresponding to regions of homology
between mouse ErbB2 and mouse alpha myosin heavy (CMHC) chain were synthesized by the
Yale Keck Facility and had the following sequences: ErbB2 p290 (amino acids sequence:
YTFGASCVTTCPYNYL) and CMHC p114 (amino sequence: YTYSGLFCVTVNPYKWL).

Immunization of mice.
For primary immunization, 100 µg vaccine antigen in 100 µl phosphate buffered saline (PBS)
was emulsified at 1:1 ratio in CFA. For boosts, a similar amount of antigen was emulsified at a
1:1 ratio in IFA. For control mice, 100 µl PBS was emulsified in an equal volume of CFA for
primary immunization or IFA for secondary immunization. Three separate experiments were
performed with the following groups of mice: Experiment 1: 10 Balb/c and 3 FVB ratErbB2+
mice; Experiment 2: 10 Balb/c mice; and Experiment 3:10 FVB ErbB2+ mice. Mice were
boosted at 3 weeks and 2 months after the primary immunization. This immunization scheme was
chosen based on prior experiments. All injections were given intra-peritoneally. All protocols
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were consistent with the accepted guidelines of the National Institutes of Health and for the care
and use of laboratory animals and were approved by the Yale University Institutional Animal
Care and Use Committee.

ELISA Assays
ELISA plates were coated with humanized recombinant ErbB2 (15 µg/ml), myosin (?µg/ml). or
peptides (p601, p290, or p114) at a concentration of 50 µg/ml in ethanol 50 µl/well). The plates
were incubated for 2 hours at room temperature. Plates were decanted and washed three times
with PBS with .05% Tween (PBST). After blocking with 3% bovine serum albumin (BSA) in
PBST (or 5% BSA in the case of peptides) (100 µl per well) for one hour at room temperature
(RT), the solution was decanted and plates were washed three times with PBST. Wells were then
incubated with 1:100 dilution of mouse sera or 1:250 dilution of anti-human antibodies in .3%
PBST (100 µl/well) for two hours at RT. Plates were washed three times with PBST as before.
100 µl of alkaline-phosphatase-conjugated anti-mouse or anti-human IgG diluted 1:1000 in 0.3%
PBST was added to each well (Southern Biotech). Plates were incubated at room temperature for
1.5 hours. After washing four times with PBST, 50 µl of reconstituted p-Nitrophenyl Phosphate
(PNPP) prepared according to the manufacturer’s instructions (Sigma) was added to each well
and left at RT. O.D. 405 was measured every 15 minutes for up to 2 hours using a Biotek Synergy
HT ELISA plate reader.

Western Blot Analysis
Purified ErbB2 extract (courtesy of Samuel Bouyain, PhD Johns Hopkins School of Medicine)
was run in a 7.5% SDS-PAGE. The gel was electroblotted onto pure nitrocellulose membrane
(Bio-Rad Laboratories, Hercules CA). After verification that the protein was present on the
nitrocellulose by Ponceau Red staining, the membrane was washed 3 times with PBST and
blocked with 3% BSA in PBST for 1.5 hours. After washing 3 times with PBST, the membrane
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was left in 1:100 dilution of mouse sera overnight (20 µl of mouse sera in 2.0 mL of .03% BSA).
After washing with PBST, the membrane was then incubated with a 1:XX dilution of alkaline
phosphatase-conjugated anti- mouse IgG (Southern Biotech,) in PBS for 1.5 hours. After washing
with PBST, the membranes were developed with BCIP/NBT substrate for 2-5 minutes. Negative
control included normal mice sera. Positive control included C-Neu monoclonal antibody
Herceptin, and sera from mice immunized with p601 in other experiments with proven reactivity
to p601.

Blots were also produced with heart cell lysates at a volume of 100 µl per gel. The heavy chain
cardiac myosin antibody used was diluted to a concentration of 1 µg/ml with .03% BSA/PBST.

Preparation of Heart Lysates
Mice were killed by cervical dislocation after deep anesthesia with inhaled isofluorane according
to Yale Animal Care and Use Guidelines. Hearts were isolated and the apices and atria processed
for imaging (see below). The remainder was placed in a centrifuge tube with 1 ml cell lysis
buffer (20 mM Tris pH 8, 200 mM NaCl, 0.1% Triton) + protease inhibitor and 1 ml of cell lysis
buffer, for a total of 2 ml. The tissue was homogenized and placed on ice for 10 minutes and
subsequently centrifuged at 12,000 rpm for 5 minutes at 4oC. The supernatant was then placed
into eppendorf tubes and frozen.

Immunoprecipitation of myosin from heart lysate
5 µg of monoclonal anti-myosin antibody (Abcam) was added to protein A sepharose beads (4
mg) in a total volume of 4 ml immunoprecipitation buffer (63) buffer (composition of buffer?)
and incubated overnight at 4°C. The next day, beads were spun for 1 minute at 14,000 rpms.
After the supernatant was removed, 200 µl of IP buffer and 100 µl of heart lysate was added to
the solution, after which it was incubated overnight at 4°C. After washing the beads once with IP
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buffer, the supernatant was aspirated and 80 µl of 2x sample buffer was added, after which it was
frozen at -80°C. In preparation for running in the gel, the solution was thawed, boiled for 10
minutes, and spun at 14,000 rpms for one minute. The supernatant was then removed and loaded
onto the gel.

Preparation of Hearts for Immunofluorescence Staining.
Heart apices and atria were either processed in periodate-lysine-paraformaldehyde (PLP) or
placed immediately into OCT or 10% formalin. Specimens placed in OCT were flash frozen on
dry ice or liquid nitrogen and stored at -80°C for future cryosectioning. Formalin-fixed specimens
were sent to the Yale Pathology Lab for paraffin embedding and sectioning. For PLP fixation,
tissues were placed in 0.1 M phosphate buffer containing 75 mM lysine, 10 mM NaIO4 and 0.7%
paraformaldehyde. After incubation overnight at 4oC, the tissues were rinsed twice in 0.1M
phosphate buffer and placed in 0.1M phosphate buffer containing 30% sucrose until the tissues
sedimented due to a change in density. Tissues were then removed from the solution, flash frozen
in OCT and stored at -80oC.

Immunofluorescence Staining of Heart Tissue
Formalin Embedded Tissue:
Slides were deparaffinized by heating to 60°C for 20 minutes. They were then immersed in used
xylene and new xylene for 20 minutes each, respectively. The slides were washed and rehydrated
by submersion in gradually decreasing concentrations of Ethanol: starting with 100% EtOH for 1
minute and ending with 70% EtOH for 1 minute. They were placed in streaming tap water for 5
minutes, then situated in 1 M Citric Acid (pH 6.0) in PT module, a device that warms the slides
mildly, to retrieve antigens from tissues. After washing with tap water, the slides were submerged
in endogenous peroxidase block (10 mL H2O2 and 390 mL Methanol), incubated for 30 minutes
in the dark at room temperature, and then washed 2 x 30 seconds in ddH20. After washing for 5
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minutes in TBST and TBS, respectively, non-specific antigens were blocked by incubating slides
in 0.3% BSA in TBST for 30 minutes at room temperature. After this step, the primary antibodies
were added to the slides (in .3% BSA in TBST in a 1:100 dilution of anti-myosin antibody) and
allowed to incubate O/N in the dark at 4°C. The following day, the slides were subjected to three
7 minute washes in TBST, TBST, and TBS respectively. The secondary antibody (anti-goat IgG
FITC at a 1:50 dilution in 0.3% TBST) was added for 1.5 hours at room temperature in the dark.
Afterwards, the slides were washed for 10 minutes in TBST, then 7 minutes each in TBST and
TBS respectively. ProLong Gold was added to each slide so the nuclei could be visualized, and a
cover slip was added. After air-drying over night, the slides were viewed using a fluorescence
microscope adapted for digital photography.

OCT Frozen Tissue:
Tissue samples were cut into 5µm slices and placed onto slides. After fixation in 100% methanol
for 4 minutes, slides were washed in PBS 3x for 5 minutes. After blocking with .03% BSA in
PBST for one hour, the primary antibody was diluted and applied at a concentration of 1:50 in
.03% BSA in PBST, and left to incubate at 4°C overnight. After washing in PBS 3x for 5
minutes, secondary FITC-conjugated anti-goat IgG at a concentration of 1:50 in .03% BSA in
PBST was added. Slides were incubated for 2 hours at RT. After three 5-minute washes with
PBS, the slides were mounted with ProLong Gold and dried overnight.

Transthoracic Echocardiography:
Animals were lightly anesthetized with inhaled isofluorane (0.2 - 5% vaporized in O2) via
nosecone (1.5 l/min). Chest wall hair was removed using topical depilatory agent (Nair). The
chest wall was thoroughly washed with water to prevent dermatitis. Two-dimensional M-mode
and Doppler echocardiography was performed via transthoracic long-axis and short-axis views
using a 15-MHz probe (Sonos 5500; Hewlett-Packard, Palo Alto, CA, USA) or a 40-MHz probe
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(Vevo770; Visualsonics, Toronto, ON, Canada). Long-axis measurements at the minor chord
dimension were taken in a standard long-axis view. Short-axis measurements were taken just
below the level of the mid-papillary muscle. At least 5 consecutive beats of the left ventricular
internal diameter (LVID) were taken of both end-diastole and end-systole in each view. These
measurements were then averaged to calculate both end-diastolic fraction shortening as well as
ejection fraction. Echocardiography was performed by trained operators. All procedures were
approved by the Yale University Institutional Animal Care and Use Committee.

Echocardiography Analysis:
The left ventricular (LV) echocardiogram was assessed in both parasternal long-axis and shortaxis views. End-systole and end-diastole were defined as the phase in which the smallest or
largest LV area was obtained. Left ventricular end-diastolic dimension (LVEDD) and left
ventricular end-systolic dimension (LVESD) were measured from the LV M-mode at the midpapillary muscle level. The following parameters were measured: LVEDD, LVESD, and
percentage fractional shortening (%FS), calculated as [(LVEDD LVESD)/LVEDD] x100. LV
ejection fraction was measured indirectly using the statistical software program included with the
echocardiography machinery and via Excel.
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RESULTS

1.

Immunization of Balb/c mice with the p601 vaccine induces antibodies to p601. Mice

were immunized and boosted at 3 weeks and at 2 months after the primary immunization. To
detect the production of anti-p601 antibodies, mice were bled prior to the 2nd boost at 2 months
and again at 5 months for final levels of antibodies. Figure 3 demonstrates the strength of
response as tested by against the p601 peptide. All mice demonstrated a strong response to p601
as compared to negative controls, and responses were equivalent to those of the positive controls.

Figure 3: ELISA detection of p601 antibodies in sera of Balb/c mice after p601
vaccination. Preboost refers to blood samples obtained immediately prior to the 2nd boost at
2 months. Post-boost refers to samples taken at 5 months.
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2. Immune sera from p601 immunized Balb/c mice contain antibodies that bind rErbB2.
An ELISA was performed with the same sera against humanized rErbB2 (Figure 4). The response
to rErbB2 varied; four mice out of ten did not demonstrate high levels of detectable anti-rErbB2
antibodies.
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Figure 4: ELISA detection of antibodies to rErbB2 in sera of Balb/c mice immunized with p601
vaccine.

The variable reactivity of p601 immunized mouse sera with rErbB2 as detected by ELISA could
indicate that conformational changes were obscuring binding of p601 antibodies to the protein
epitope. Because the rErbB2 was denatured during SDS-PAGE, it would be expected to expose
linear epitopes on immunoblot. We therefore tested whether p601 immunized mouse sera reacted
with rErbB2 on immunoblot (Figure 5). This confirmed that our mice sera contained antibodies
that bound ErbB2.
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3. Antibodies from p601-immunized Balb/c mice bind proteins in heart lysates, including
myosin heavy chain. Our next step was to determine whether our sera contained antibodies that
bound ErbB2 on heart lysates. A BLAST search revealed that ErbB2 on mouse heart, tumor
tissues, and other parts of the body are identical. The heart lysate blots revealed that our
immunized mice sera were binding to proteins on the heart lysate as compared to controls (Figure
6). The bands were between 116-204 kda, within the range where the ErbB2 receptor lies.
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In order to identify proteins that the immunized mice sera and Herceptin were binding on the
heart cell lysate, mass spectrometry analysis was performed on bands cut out of a membrane of
normal heart lysate corresponding to the regions of the bands on the immunoblot. Three proteins
were identified:

1.
2.
3.

Alpha Cardiac Myosin Heavy Chain (mus musculus): Molecular Weight 223410
Chain E, Leech-Derived Tryptase Inhibitor Trypsin Complex: Molecular Weight 23457
Embryonic muscle myosin heavy chain: Molecular Weight 188548

A BLAST search was performed with all of these proteins and mouse ErbB2. Alpha cardiac
myosin heavy chain (α-CMHC) contained a region with greatest homology to ErbB2 and
demonstrated the strongest signal on the blot. The sequences that were closely aligned were 16
and 17 amino acids for ErbB2 and α-CMHC, respectively, where there were 9 overlapping,
identical amino acids. The sequences were YTFGASCVTTCPYNYL between amino acids 290
and 305 and YTYSGLFCVTVNPYKWL between amino acids 114 and 130 for ErbB2 and
myosin heavy chain, respectively. Spectrometry analysis was repeated twice, with the same
proteins revealed each time.

A BLAST search was also performed with human ErbB2 and α-CMHC. The results were similar
to those in mice; there was a region of 9 overlapping amino acids between amino acids 115 and
149 and 289 and 332 in ErbB2 and α-CMHC, respectively. Sequences and regions of homology
for human proteins are demonstrated below:

ErbB2: 259

YTF--GASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAE---DGTQRCE 302
YT+ G CVT PY +L
P++N EV A
G +R E
α-CMHC: 115 YTYSGLFCVTVNPYKWL---------------------PVYNAEVVAAYRGKKRSE 149
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We found crystallographic structures for tarantula myosin and human ErbB2 to assess where the
regions of homology lie on the two molecules. The homologous region of the ErbB2 chain lies
exposed on the extracellular domain(83). Myosin is an intracellular protein and the peptide
sequence we identified lay on its ATP-binding region. The images with the sequences highlighted
in red are found below.

Three-dimensional reconstruction of tarantula myosin filaments with red region indicating
myosin peptide demonstrating homology with ErbB2(84)

Three-dimensional reconstruction of human ErbB2 with red region indicating ErbB2 peptide
demonstrating homology with myosin. (84)
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This put forth the speculation that the antibodies induced by p601 immunization also targeted
alpha cardiac myosin heavy chain complex on mice hearts. (84)

4. Antibodies in sera of patients treated with Herceptin bind synthetic peptides representing
regions of homology between α-CMHC and ErbB2. Two peptides corresponding to mouse αCMHC amino acids 114-139 (p114) and mouse ErbB2 amino acids 290-315 (p290) were
synthesized and tested for reactivity with Herceptin.

Figure 7: ELISA assay measuring Herceptin binding to p114, p290,
and rErbB2 as compared to normal mouse sera and blank plates
(sans primary).
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The results indicate that Herceptin binds to p114 and p290 to a significant degree compared to
blocked plates, blank plates and normal mouse sera. The positive control rErbB2 binds most
strongly to Herceptin, followed by p290 and then p114.

Sera from breast cancer patients treated with Herceptin were also analyzed for reactivity to p114
and p290 (Figure 8). The assay below demonstrates that the sera of breast cancer patients treated
with Herceptin had a weak, but detectable reactivity to p114 or p290. The patient sera
demonstrated a strong response to rErbB2, however. Compared to NHS controls, the Hu Breast
CA sera had more pronounced binding to all peptides. Of note, Herceptin did not illustrate a
strong response against p114 or p290, unlike results shown in Figure 7. This experiment was
repeated several times, with variable results in Herceptin binding as above.

Figure 8: ELISA assay p114, p290 and rErB2 using sera from breast cancer patients
treated with Herceptin (Hu Breast CA Sera) p114, p290 and rErbB2 as compared to a
blocked plate. NHS=Normal Human Sera.
5.
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Antibodies in sera of mice immunized with p114 react with p290 but not p601. We next
examined the mouse response to immunization with p114 and p290. Balb/c mice were immunized
according to the protocol used for p601. ELISAs were performed with both myosin and ErbB2
(Figure 9) and with individual peptides (Figure 10).

Figure 9: ELISA assay of p290 and p114 immunized mice sera against myosin, ErbB2 and p601
as compared to a blocked plate. Sera from p601-immunized mice with proven strong p601
reactivity were used.

The p290-immunized mice sera did not demonstrate binding to any of the antigens, suggesting
this peptide is not immunogenic. The p114 immunized mice sera demonstrated a strong response
to the myosin and an intermediate response to rErbB2 as compared to a blocked plate. These mice
sera did not demonstrate a signal against p601. Finally, select p601 immunized mice sera
demonstrated some degree of reactivity against both myosin and ErbB2 when compared to a
blocked plate.
The p290 and p114-immunized mice sera did not demonstrate a strong signal on ELISA against
rErbB2. However, p114-immunized sera demonstrated strong reactivity against p114 as well as
moderate reactivity against p290. The p601-immunized sera illustrated a strong signal against
rErbB2 but not against p114 or p290.
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Figure 10: ELISA assay of p290 and p114 immunized mice sera against p114, p290,
and rErbB2 (rHer2) as compared to a blocked plate. One p601-immunized sera that had
previously demonstrated strong reactivity against rHer2 in both ELISA and western blot
is also shown in the last column.

We also tested these mice sera for binding to rErbB2 via Western blot (Figure 11). Our known
positive control as well as our p601 immunized mice sera reacted strongly. P290 and p114
immunized sera, however, did not demonstrate bands against the extracellular domain of rErbB2.
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We repeated the heart cell lysate blot to determine whether the p290 and p114 immunized sera
illustrated reactivity in the same region as the p601 sera. Results are shown in Figure 12 as
follows:

Our positive control mice sera demonstrated a strong band in the 180 kd region as before, in the
same region where ErbB2 would be found. Our positive control demonstrated binding that was
comparable to p114 sera. Finally, the p290 exhibited selective binding, with three of four mice
sera demonstrating a signal. However, the signal was not as strong as p601 immunized sera or
p114 sera. Finally, proteins detected by the positive controls (p601 immunized sera) and p114immunized sera were in a similar location as the protein detected by the heavy chain cardiac
myosin antibody.

We decided to examine whether the binding demonstrated in our heart lysate blot was specific for
myosin. Myosin was immunoprecipitated from heart lysates with a commercialized, monoclonal
mouse anti-myosin antibody. The gel of this experiment is found in Figure 13.
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Figure 13: Gel of immunoprecipitated myosin and molecular weight marker. The left lane
represents a dilution containing 5 µl protein and 5 µl PBS; the middle lane contains 10 µl of
protein with no PBS.
Based on the results of gel above, the western blot was run with 50 µl of immunoprecipitated
protein in a large well.

The experiment confirmed the suspicion that p601 immunized sera binds to cardiac myosin more
than PBS immunized controls. The fact that our p290 and p114 sera also demonstrated signal in
this blot suggests that one reason for this binding may be due to the homology of ErbB2 and
myosin binding regions we identified. In this scenario, two self-peptides have been rendered as
foreign due to the immunogenic response initiated by peptide vaccination.
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6.

FVB ratErbB2 mice but not Balb/c mice immunized with p601 develop cardiac

dysfunction.
Our next step was to determine whether immunization with p601, p114 or p290 could induce
cardiac dysfunction in mice. Echocardiography was performed before and 3 months after initial
immunization. Ejection fraction was derived from calculations of left ventricular (LV) internal
dimension in diastole and systole, LV posterior wall thickness, LV anterior wall thickness,
approximate LV volume in diastole and systole, as well as fractional shortening. Results are
reported as the mean ± standard deviation of values obtained from mice within a group and show
no differences between sham and p601-immunized Balb/c mice at 3 months (Table II) or 6
months (Table III) after initial immunization.

Table II: Average ejection fraction of Balb/c mice assessed 2.5 months after initial immunization
Average LVEF (%)
Non-immunized (N=6)

49.7 ± 5.36

Sham-immunized (N=4)

60.34 ± 4.19*

P601-immunized (N=6)

58.74 ± 3.94

*Sham vs. p601 immunized p = 0.33

Table III: Average ejection fraction of Balb/c mice assessed 6 months after initial immunization
Average LVEF (%)
Sham-immunized (N=5)

56.6 ± 6.55

P601-immunized (N=5)

57.4 ± 4.6

*Sham-immunized vs. p601 immunized p = 0.43
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This was not the case for FVB ratErbB2 mice, which showed a statistically significant decrease in
ejection fraction after p601 immunization.

Table IV: Average ejection fraction of FVB mice assessed 6 months after initial immunization
Average LVEF (%)
Non-immunized (N=3)

79.56±2.43

P601-immunized (N=3)

71.35±7.09

*Sham-immunized vs. p601 immunized p = 0.02

We also examined the cardiac function of mice immunized with p114 and with p290 (Table V).
Immunization with those peptides did not lead to cardiac dysfunction in Balb/c mice.

Table V: Average ejection fraction of Balb/c mice assessed 6 months after initial immunization
with p114 or p290.
Average LVEF (%)
Sham-immunized (N=5)

56.6 ± 6.55

P114-immunized (N=4)

49.87 ± 8.5

P290-immunized (N=4)

55.1 ± 7.6

*Sham-immunized vs. p114 immunized p = 0.15; Sham-immunized vs. p 290 immunize p=0.36

Echocardiography also revealed cardiac arrhythmias in p601-immunized FVB ratErbB2 (Figures
16 and 17) but not Balb/c mice (Figure 15).
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Figure 15: Baseline Echocardiogram and EKG on a Normal balb/c Mouse.
*Note the consistent and regular variation in beats per minute based on respiratory cycle

Figure 16: Echocardiogram/EKG of p601 immunized FVB ratErbB2 mouse 8934.

Figure 17: Echocardiogram/EKG of p601 immunized FVB ratErbB2 mouse 8935.
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In animals 8934 and 8935, note the premature contractions (either atrial or ventricular). The beats
per minute range from 80 to 152 within rhythm strips shown and are irregular.

7.

Immunofluorescence staining of heart tissue of p601-immunized mice reveals IgG

deposition.
To begin to understand the basis for cardiac dysfunction in FVB ratErbB2 mice immunized with
p601, we examined hearts by immunofluorescence staining to look for evidence of antibodies
binding the tissue. Before assessing the reactivity of immune sera with heart tissue by
immunofluorescence staining, we tested for presence of endogenous antigen-antibody complexes
on the mice hearts with a FITC-conjugated anti-mouse IgG secondary alone. The results
demonstrated increased secondary staining in hearts from FVB ratErbB2 mice immunized with
p601 peptide (Figure 18A-C), compared to PBS immunized Balb/c (Figure 18D) and normal
(non-immunized) FVB ratErbB2 controls (Figure 18E).

Figure 18:
Immunostaining on mice hearts fixed in formalin:

A. Mouse 8934—FVB ratErbB2 p601 immunized. Stained with secondary (goat anti-mouse IgG
FITC) only, sans primary. Left panel 10X, right panel 40X.
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B. Mouse 8935—FVB ratErbB2 p601 immunized. Stained with secondary (goat anti-mouse IgG
FITC) only, sans primary.

C. Mouse 8936—FVB ratErbB2 p601 immunized. Stained with secondary (goat anti-mouse IgG
FITC) only, sans primary.

D. Mouse 459—Balb/c- PBS immunized;. Stained with secondary (goat anti-mouse IgG FITC)
only, sans primary.
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E. Normal Mouse Heart—FVB MMTV not immunized. Stained with secondary (goat anti-mouse
IgG FITC) only, sans primary.

The two mice (8934 and 8935, Figure 18A and 18B) that had arrhythmias on EKG demonstrated
brighter staining than mouse 8936 (Figure 18C) whereas the FVB ratErbB2 p601 mouse did not
demonstrate arrhythmias on EKG. This put forth the suggestion that the arrhythmias may be
correlated with the antigen-antibody complexes on the heart tissue surface. Furthermore, PBS
injected mouse 459 (Figure 18D) demonstrated some level of background as compared to a
Normal Mouse Heart (Figure 18E), but the signal was less when compared to mice 8934 and
8935.

Similar increased staining of heart tissue from p601-immunized Balb/c mice from two separate
experiments (Figure 19A-C) in comparison to sham-immunized controls (Figures 19D-F) was
also seen. Experiment 1 mice had echoes taken and were killed 6 months after initial injection.
Experiment 2 mice had echoes taken and were killed 3 months after initial injection.
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Figure 19:

A. Mouse 8933—Balb/c p601 immunized, Exp.1. Stained with secondary (goat anti-mouse IgG
FITC) only, sans primary. Left panel 10X, right panel 40X.

B. Mouse 372—Balb/c p601 immunized, Exp.2. Stained with secondary (goat anti-mouse IgG
FITC) only, sans primary. Left panel 20X, right panel 40X.

C. Mouse 379—Balb/c p601 immunized, Exp.2. Stained with secondary (goat anti-mouse IgG
FITC) only, sans primary. Left and right panels 20X.

46

D. Mouse 224—Balb/c PBS immunized, Exp. 2. Stained with secondary (goat anti-mouse IgG
FITC) only, sans primary. Left and right panels 20X.

E. Mouse 459—Balb/c PBS immunized, Exp. 1. Stained with secondary (goat anti-mouse IgG
FITC) only, sans primary. Left and right panels 20X.

F. Mouse 8924—Balb/c PBS immunized, Exp.1. Stained with secondary (goat anti-mouse IgG
FITC) only, sans primary. Left panel 20X; right panel 10X.
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G. Normal Mouse Heart—Balb/c non-immunized, Exp.2. Stained with secondary (goat antimouse IgG FITC) only, sans primary. Left and right panels 20X.

Figures 19A through 19C demonstrate a stronger signal with secondary as compared to Figures
19D through 19F. All images from immunized mice demonstrate a stronger signal as compared to
normal mouse heart tissue (Figure 19G). This suggests that although mice injected with PBS may
demonstrate some degree of background staining, those mice injected with our peptide vaccine
may have antigen-antibody deposition on the heart surface.

Western blot with heart lysate and tissue staining of mice hearts suggested that there was
selective binding of p601-immunized sera to something within the heart tissue, and that there may
have been antigen-antibody depositions present on the heart surface. Interestingly, the FVB mice
immunized with p601 that had cardiac abnormalities also demonstrated a strong signal with FITC
immunofluorescence (Figure 18A and 18B, Mouse 8934, 8935) as compared to a p601
immunized mice without cardiac abnormalities (Figure 18C, Mouse 8936), PBS immunized
Balb/c controls (Figure 18D, Mouse 459), or non-immunized FVB mouse controls (Figure 19,
Normal Mouse). These data imply that the cardiac defects could be in part due to the
immunization of the mice, and perhaps due to an immunological reaction within the myocytes,
resulting in premature contractions.
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Immunofluorescence staining on p290 and p114-immunized mice heart tissue
In addition to western blots, we stained p290 and p114 immunized mice hearts (Figures 20). The
purpose of this was to determine the presence of antigen-antibody deposits on the heart surface.

Figure 20:

A. Mouse 41—Balb/C p290 immunized. Stained with secondary (goat anti-mouse IgG FITC)
only, sans primary. Left panel 10X; right panel 20X.

B. Mouse 43—Balb/c p290 immunized. Stained with secondary (goat anti-mouse IgG FITC)
only, sans primary. Left panel 10X; right panel 20X.
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C. Mouse 47—Balb/c p114 immunized. Stained with secondary (goat anti-mouse IgG FITC)
only, sans primary. Left and right panels 20X.

D. Mouse 50—Balb/C p114 immunized. Stained with secondary (goat anti-mouse IgG FITC)
only, sans primary. Left panel 10X; right panel 20X.

E. Mouse 8924—Balb/c PBS immunized. Stained with secondary (goat anti-mouse IgG FITC)
only, sans primary. Left panel 10X; right panel 20X.
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F. Mouse 8928—Balb/c PBS immunized. Stained with secondary (goat anti-mouse IgG FITC)
only, sans primary. Left panel 10X; right panel 20X.

Figures 20A through 20C demonstrated a slightly stronger signal with secondary as compared to
Figures 20E and 20F. This suggests that although mice immunized with PBS may demonstrate
some degree of background staining, those mice immunized with either p114 and p290 may have
antigen-antibody deposition on the heart surface.

The question became: does the enhanced signal by the anti-IgG conjugate alone on mice hearts
(p601, p114, and p290) indeed detect deposition of immune complexes and an autoimmune
response? This could best be answered by testing for complement deposition and in particular C3,
which is produced in all three pathways of complement activation. The three pathways in which
complement is activated include the classical pathway (due to activation of antigen: antibody
complexes), Mannan binding-Lectin pathway, and the alternative pathway (which occurs on the
surface of pathogens independent of antibodies)(74).

In order to test for the activation of complement due to the classical pathway, p601, p114, and
p290-immunized mice hearts were stained with FITC-conjugated antibodies to mouse C3 and
compared to normal controls. The results are shown in Figure 21 below:
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Figure 21:

A. Normal Mouse: Balb/c non-immunized. Stained with anti-C3 FITC labeled antibody. Left
panel 20X; right panel 40X.

B. Mouse 384: Balb/c p601 immunized. Stained with anti-C3 FITC labeled antibody. Note the
deposits of fluorescence on the image on the left, and magnified on the right. Left panel 20X;
right panel 40X.

C. Mouse 47—Balb/c p114 immunized. Stained with anti-C3 FITC labeled antibody. Note the
lack of fluorescent deposits on this mouse heart. Left panel 20X; right panel 40X.
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D. Mouse 40—Balb/c p290 immunized. Stained with anti-C3 FITC labeled antibody. Note the
lack of fluorescent deposits on this mouse heart. Left panel 20X; right panel 40X.

The staining above reveals that there was increased complement deposition on the heart in mice
immunized with the p601 vaccine as compared to normal mice, and p290 and p114-immunized
mice. This finding is consistent with the ELISA, Western blot, and immunofluorescence results
of p601-immunized mice, suggesting that autoantibodies may be depositing on the heart surface,
resulting in complement activation.

Summary of Results
P290 injected Mice Balb/c—
Mouse ID

ELISA ErbB2 OD
405

rErbB2
Western

Heart Lysate

IP Lysate

Tissue Stain

40

.1

-

-

-

-

41

.1

-

+

+

++

43

.1

-

+

+

-

45

.1

-

+

+

+
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P114 injected Mice Balb/c
Mouse
ID

ELISA ErbB2 OD
405

rErbB2
Western

Heart Lysate

IP Lysate

Tissue
Stain

46

.1

-

-

+

-

47

.1

-

-

-

++

48

.1

-

+

+

+

49

.2

-

+

+

No Data

50

.3

-

+

+

++

After having these peptides synthesized, only p114-immunized sera displayed reactivity via
ELISA against both p114 and p290. However, some of the p290 sera had signals via a heart
lysate blot and immunoprecipitated myosin, indicating some degree of an immune response. The
p290-immunized mice also demonstrated binding via heart lysate western blot and
immunoprecipitated myosin, although their signal was not as strong as p601 immunized mice
sera. P114-immunized mice that had a strong signal via western blot (heart lysate) also had
increased signal via tissue staining. All except one mouse that had strong FITC tissue signals also
had a strong signal in heart lysate and immunoprecipitated western blots.

8.

Immunization of mice with p601 results in structural changes within FVB mouse

hearts. Our results showing an association between level of secondary FITC-conjugated antimouse IgG binding to heart sections and cardiac dysfunction suggest that there could be structural
abnormalities in the hearts of immunized mice. To assess this, we analyzed formalin-fixed heart
sections by H&E staining (Figure 22).
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Hematoxylin and eosin staining on mice hearts
Figure 22:

A. Mouse 8934—FVB ratErbB2 p601 immunized.

Mouse 8934 demonstrated abnormalities on echocardiogram and enhanced immunofluorescence
staining compared to PBS and normal mouse controls (Figure 16, 18A). H&E staining revealed
destruction of sarcomeric structure and leukocyte adhesion to surface of arteriolar endothelium.

B. Normal Mouse Heart—FVB ratErbB2 non-Immunized.
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Compared to Figure 13A, Figure 13B revealed intact sarcomeres and myofibrillar array. There
were also no leukocytes adhering to endothelium.

C. Mouse 8935—FVB ratErbB2 p601 immunized.

D. Mouse 459—Balb/c PBS immunized. Notice intact sarcomeres and no leukocytes
around arterioles.
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E. Mouse 43—Balb/c p290 immunized. Notice intact sarcomeres and no leukocytes around
arterioles.
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DISCUSSION:
Vaccine model for studying Herceptin effects on cardiac function
One of the greatest challenges to studying potential mechanisms whereby Herceptin leads to
adverse cardiac effects in humans is the absence of a suitable laboratory animal model for initial
studies. Herceptin is a fully humanized monoclonal antibody and does not bind strongly to
mouse ErbB2. In order to bypass this dilemma, our lab tested several peptide sequences on the
extracellular domain of both mouse and human ErbB2 as potential vaccine antigens. The results
of those studies revealed that p601 is a potential vaccine antigen because it is immunogenic,
produces antibodies that bind ErbB2, and in preliminary studies could suppress ErbB2+ tumors,
similar to Herceptin.

The main difference between giving an animal a protein as a vaccine versus a purified
monoclonal antibody is the type of antibodies formed; a vaccine induces a polyclonal B cell
response that produces antibodies targeting multiple epitopes (or antigenic determinants) on the
immunogen—in this case, ErbB2. The mice in our model were immunized with a peptide that
induced a response not only to the peptide but also to at least one other antigenic determinant on
ErbB2 (p290), and possibly other epitopes as well. Our studies suggest that a similar expanded
immune response may occur in patients taking Herceptin. Sera from patients treated with
Herceptin contained not only antibodies that bound ErbB2, but also those that reacted with a selfprotein, myosin. This means that the immune effects of a monoclonal antibody may be more
complex than was initially assumed. When an antibody targets a cellular receptor and induces
damage, self-proteins are released into the periphery. These self-proteins are then taken up by
antigen-presenting cells and induce further immune response, via of T and other immune cells.
Thus, the self-proteins released in this process may become self-immunogens, resulting in a
polyclonal response to multiple protein determinants on the same self-particle(77). In the case of
patients treated with Herceptin, an immune response can occur against non-dominant epitopes on
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ErbB2 and on proteins with which it may form complexes. Unpublished data from our laboratory
indicate that there exist such epitopes in the sera of patients being treated with Herceptin.

Molecular mimicry with anti-ErbB2 vaccine therapy
After immunizing mice with p601 and testing for p601 and ErbB2 binding by ELISA and western
blot, our projects’ main focus was to determine the cardiac effects of our vaccine. A western blot
with heart lysate revealed strong binding with our sera as compared to PBS and negative controls,
suggesting that antibodies to p601 (or to ErbB2) could be binding something in the heart. Our
studies revealed a homologous region on alpha cardiac myosin heavy chain (α-CMHC) and
ErbB2, implying that Herceptin and our immunized mice sera could potentially bind to a part of
alpha cardiac myosin heavy chain. α-CMHC is predominant in the adult mouse heart and holds a
93% homology to beta cardiac myosin heavy chain(85). Not surprisingly, the homologous
sequence we discovered between α-CMHC and ErbB2 also exists between β-CMHC and ErbB2
in both humans and mice. The presence of these sequences in α and β myosin in both species
implies that these results could potentially be applicable to humans. However, the differences
between these two isoforms should be mentioned. α-CMHC has a high actin-activated ATPase
activity and is associated with an increased shortening velocity. This differs from β-CMHC,
which is associated with a lower ATPase activity and has a decreased shortening velocity(86).
These isoforms are developmentally regulated; in all mammals, the β isoform is predominant in
utero. However, in small mammals such as mice, the α isoform becomes predominant after birth;
in large mammals such as humans, the β isoform is prevalent throughout life. Furthermore, the
predominant isoform can vary throughout life, depending on environmental influences and this
regulation is via transcription of genes. For instance in humans, α-CMHC depends on the
presence of thyroid hormone; without thyroid hormone, the gene regulating the isoform is not
transcribed(86). The opposite is true for β-CMHC. Interestingly, disease states such as heart
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failure or hypertrophy can alter the levels of isoform present. In mice with heart failure, the
predominant isoform changes from α-CMHC to β-CMHC. In fact, even in humans with heart
failure the small percentage of α-CMHC is also down-regulated and found to be
undetectable(85). One theory proposed for this shift is that β-CMHC may preserve function by
increasing the energy efficiency of the heart. Interestingly, this isoform shift has also been found
to be reversible after regression of cardiac hypertrophy. After aortic banding and de-banding, the
levels of α-CMHC varied, with increased α-CMHC found after debanding and β-CMHC found
after banding(87)

Patients receiving the monoclonal antibody Herceptin initiate a humoral response to ErbB2+
tissues. However, the homology between our discovered sequences between the extracellular
domain of ErbB2 and intracellular myosin could initiate an immune response in the heart as well.
Such a sequence of events is similar to molecular mimicry, a pathologic process that has been
well described in a variety of disease processes.

Molecular mimicry, or the homology between foreign and self-peptides, is well known for its role
in rheumatic heart disease. Zabriskie and colleagues were amongst the first to demonstrate the
antigenicity of streptococcal antibody against cardiac muscle, in particular cardiac myosin(88).
Although myosin is an intracellular protein, scientists have developed theories of the mechanism
of cardiac pathology. Studies have found monoclonal antibodies react not only with myosin in
myocardium, but also in valvular endothelium. Roberts and colleagues found evidence that
surface valvular endothelium was activated with the expression of vascular cell adhesion
molecule-1, allowing extravasation of CD4+ and CD8+ T lymphocytes through the endothelium
into the valve(89). In addition, Fae and colleagues found that T cell clones from the mitral valve
reacted and myocardium recognized and reacted with human cardiac myosin β-chain (light
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fragment)(90). Therefore, with progression of lesions and scarring in the valve, and epitope
spreading (spreading of the immune response to new epitopes), cross reactive T cells may then
come to target other components of the heart as well, including β-light chain myosin and valvular
proteins, likely due to homology or structural similarities—assisted by activation and
extravasation of the endothelium(90).

A similar mechanism of cardiac death may be occurring in patients taking Doxorubicin
concurrently with Herceptin. As mentioned previously, the effects of oxidative damage due to
anthracyclines can result in disruption of the cardiac sarcomeric structure. With loss of
myocardial structure, exposure of internal fragments of the heart (such as myosin) could become
potential targets in patients receiving Herceptin therapy. The homology between the extracellular
ErbB2 domain and cardiac myosin has been well established via our studies. The binding affinity
of Herceptin for our peptides via ELISA has also been established. Therefore, one can make the
link that given the right environmental factors (sarcomere destruction, exposure of internal
myosin fragments), Herceptin could target internal myosin fragments.

Mice immunized with p601 that developed echocardiographic abnormalities had
immunofluorescence evidence of immune complex deposition and also demonstrated structural
cardiac abnormalities (Figure 13), including sarcomere disruption and leukocyte adhesion to
endothelium, neither of which was demonstrated in normal mice hearts. However, the reason for
this destruction is unknown since our mice were not concomitantly given Doxorubicin or other
cardiotoxic agents.

A Potential Model for p601-induced Cardiac Injury.
One theory for destruction of heart tissue is as follows. Cardiac dysfunction was seen in mice of
a particular strain (FVB ratErbB2) that up-regulate ErbB2 on breast tumor cells. Immunization
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with a peptide targeting ErbB2 could induce an immune reaction that is increased as compared to
Balb/c mice that do not bear tumors and do not contain increased amount of systemic ErbB2
receptors. As the peptide produces a polyclonal response and tumor cells are targeted by natural
killer cells, certain epitopes may be targeted more than others, including p114 (the ErbB2 peptide
we identified via mass spectrometry), which is part of the extracellular domain. The FVB
ratErbB2 strain of mice may also have increased ErbB2 receptors on the heart, although this
cannot be verified. The peptide vaccine may not only be inducing a targeted response against
ErbB2 on tumor cells, but also ErbB2 on the myocardium itself, resulting in the sarcomere
destruction we saw in Figure 13. With the disruption of these cardiac cells, intracellular proteins
would be exposed to the surface. And with an ErbB2 peptide domain that has already been up
regulated as outlined above, the destruction of the homologous myosin fragment (p114) would be
unproblematic. In summary, the immunological response could be occurring on tumor cells as
well as cardiac myocytes, with systemic leukocytes (including natural killer cells) inducing a
generalized inflammatory reaction. Since one of the mechanisms of Herceptin is antibodydependent cellular toxicity (via natural killer cells),(53, 54) such a theory would be within reason.
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Here, Herceptin stimulates antigen-dependent cytotoxic killing via a natural killer cell. Once
destroying the ErbB2+ tumor cell, self-proteins are released into the periphery, which are then
taken up by antigen-presenting cells.

Differences between p601 vaccine-induced and herceptin-induced cardiac dysfuntion.
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The cardiac defects that our two FVB p601-immunized mice demonstrated were not consistent
with what has been seen in patients with Herceptin-induced cardiac failure, which most often
results in a decline in baseline left ventricular ejection fraction(65). In fact, no p601-immunized
mice demonstrated depressed cardiac function (such as lower ejection fraction) as compared to
age-controls. However, extensive destruction is needed for diminished ejection fraction. Though
histological evidence on the FVB mice heart demonstrated destruction and some degree of
inflammation, this could lead to arrhythmias if present within tissues that electrically conduct. In
this way, our mice may actually be a good model for studying the cardiac effects of Herceptin.

Although two of the over twenty mice we immunized demonstrated echocardiographic
abnormalities, the majority did not. All p601, p114, and p290 immunized Balb/c mice had normal
echoes compared to age-matched controls. However, histology demonstrated leukocyte adhesion
to arteriolar surface in p601-immunized Balb/c mice, but did not have evidence of myocardial
destruction.

Both p114 and p290 mice hearts were histologically normal via H&E, although they did have
increased fluorescence when stained with non-specific anti-IgG FITC antibody. C3 staining
demonstrated no increased staining as compared to normal mouse hearts, indicating that the
background level of FITC staining was probably an artifact. These results are consistent with the
fact that p290 did not have immunogenic properties (via ELISA or western blot). These mice,
though demonstrating immunogenicity via ELISA, did not demonstrate binding to heart lysate in
western blot. Immunofluorescence staining revealed increased anti-IgG FITC, but none with antiC3 antibody, indicating that the anti-IgG FITC staining was not selectively binding and deeming
our immunofluorescence results inconclusive.
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Although our results look promising for revealing a potential immune mechanism for Herceptininduced heart failure, more studies need to be done. Since our FVB ratErbB2+ p601-immunized
mice demonstrated both arrhythmias as well as more extensive histological damage, more studies
need to be done on this particular strain of mouse. They may also be a better model to study
patients who have ErbB2+ cancer since most bear tumors. In addition to immunohistochemical
analysis we have already done with non-specific IgG and C3 staining, we could stain for
oxidative damage directly on the heart. In addition, in vivo experiments using radiolabeled
polyclonal sera that targets ErbB2 could measure perfusion in certain areas of the heart.
Furthermore, our results would theoretically be amplified if our mice were concomitantly given
Doxorubicin, which potentiates the effects of Herceptin. Finally, more comprehensive
examination of certain components of the heart, such as the bundle of His and atria, can be
prepared for potential localization of a particular area of damage that induces arrhythmias. Such
studies should be performed in parallel with age-controlled mice of the same strain.

Herceptin’s effects on the human heart
The final component of my research was to determine whether our results could translate to
humans. The only human study we carried out was an ELISA with human sera of people who had
been taking Herceptin, to determine binding with our homologous peptides and the extracellular
domain ErbB2. In the sera that strongly bound ErbB2, there was some demonstrable, but very
slight binding to the peptides. Furthermore, the positive control of Herceptin bound erratically to
our peptides in the multiple ELISAs we performed. Future experiments should include a repeat of
this ELISA, with immunized sera from more patients. These human sera can also be used in
immunohistochemistry, to determine whether it binds to mouse hearts that have been exposed to
Doxorubicin. If our hypothesis is accurate, there would be increased staining in mice treated with
anthracyclines than those not. The staining pattern in this experiment would demonstrate whether
the injury resembles other autoimmune heart diseases.
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